Eupolyphaga sinensis Walker demonstrates angiogenic activity and inhibits A549 cell growth by targeting the KDR signaling pathway

被引:26
作者
Dai, Bingling [1 ]
Qi, Junpeng [1 ]
Liu, Rui [1 ]
Zhang, Yanmin [1 ]
机构
[1] Xi An Jiao Tong Univ, Sch Pharm, Hlth Sci Ctr, Xian 710061, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Eupolyphaga sinensis Walker; vascular endothelial growth factor; A549; cells; human umbilical vein endothelial cells; THERAPY; TRANSDUCTION; CARCINOMA; CANCER; KINASE;
D O I
10.3892/mmr.2014.2387
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Eupolyphaga sinensis Walker has been reported to have anticoagulation, antithrombotic, liver protective and antitumor effects. In the present study, the inhibitory effects on proliferation of A549 human non-small cell lung cancer cells and the underlying mechanisms were examined. Firstly, three solvents, 70% ethanol, distilled water and 95% ethanol, were used to extract Eupolyphaga sinensis Walker. The MTT assay results demonstrated that the 70% ethanol extract more potently reduced the growth of A549 cells and it was therefore adopted in the subsequent experiments. Eupolyphaga sinensis Walker 70% ethanol extract significantly inhibited A549 cell migration in a time- and dose-dependent manner and inhibited human umbilical vein endothelial cell proliferation, migration and tube formation. Furthermore, Eupolyphaga sinensis Walker 70% ethanol extract effectively inhibited blood vessel formation in the established tissue model for angiogenesis. In addition, Eupolyphaga sinensis Walker 70% ethanol extract was demonstrated to inhibit the autophosphorylation of KDR, and downregulate the subsequent activation of AKT and extracellular signal regulated kinase (ERK)1/2 in A549 cells. In conclusion, these findings demonstrated that the antitumor mechanism of Eupolyphaga sinensis Walker 70% ethanol extract was through inhibiting angiogenesis. It functioned by interrupting the autophosphorylation of KDR and subsequently, AKT and ERK1/2.
引用
收藏
页码:1590 / 1596
页数:7
相关论文
共 24 条
[1]  
Aragon-Ching Jeanny B, 2009, Update Cancer Ther, V3, P182
[2]   Vascular remodeling and clinical resistance to antiangiogenic cancer therapy [J].
Bender, JG ;
Cooney, EM ;
Kandel, JJ ;
Yamashiro, DJ .
DRUG RESISTANCE UPDATES, 2004, 7 (4-5) :289-300
[3]   Signaling angiogenesis via p42/p44 MAP kinase and hypoxia [J].
Berra, E ;
Milanini, J ;
Richard, DE ;
Le Gall, M ;
Viñals, F ;
Gothié, E ;
Roux, D ;
Pagès, G ;
Pouysségur, J .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) :1171-1178
[4]   PROTEIN-KINASE-B (C-AKT) IN PHOSPHATIDYLINOSITOL-3-OH INASE SIGNAL-TRANSDUCTION [J].
BURGERING, BMT ;
COFFER, PJ .
NATURE, 1995, 376 (6541) :599-602
[5]   Angiogenesis in life, disease and medicine [J].
Carmeliet, P .
NATURE, 2005, 438 (7070) :932-936
[6]   Eupolyphaga sinensis Walker inhibits human chronic myeloid leukemia cell K562 growth by inducing G2-M phase cell cycle arrest and targeting EGFR signaling pathway and in S180 tumor-bearing mice [J].
Dai, Bingling ;
Zhan, Yingzhuan ;
Qi, Junpeng ;
Zhang, Yanmin .
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2014, 37 (03) :1177-1185
[7]   A novel tissue model for angiogenesis: evaluation of inhibitors or promoters in tissue level [J].
Dai, Bingling ;
Zhang, Yanmin ;
Zhan, Yingzhuan ;
Zhang, Dongdong ;
Wang, Nan ;
He, Langchong .
SCIENTIFIC REPORTS, 2014, 4
[8]   Vascular endothelial growth factor: Basic science and clinical progress [J].
Ferrara, N .
ENDOCRINE REVIEWS, 2004, 25 (04) :581-611
[9]   Vascular endothelial growth factor as a target for anticancer therapy [J].
Ferrara, N .
ONCOLOGIST, 2004, 9 :2-10
[10]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676